Recent AHA/ACC guidelines on cholesterol management expands the role of the clinical laboratory

Area of Science:

• Cardiovascular Medicine
• Clinical Laboratory Science
• Preventive Cardiology

Background:

• Recent American Heart Association (AHA) and American College of Cardiology (ACC) guidelines update blood cholesterol management strategies.
• The Pooled Cohort Equation for estimating 10-year atherosclerotic cardiovascular disease (ASCVD) risk is now complemented by a greater emphasis on individualized risk assessment.
• Laboratory medicine's role is increasingly critical in the prevention and management of ASCVD.

Purpose of the Study:

• To review key aspects of the new AHA/ACC cholesterol guidelines impacting laboratory practice.
• To highlight changes in low-density lipoprotein cholesterol (LDL-C) treatment targets and risk assessment methodologies.
• To underscore the evolving opportunities for clinical laboratorians in ASCVD prevention.

Main Methods:

• Review of the latest AHA/ACC guidelines on blood cholesterol management.
• Analysis of guideline components relevant to laboratory diagnostics and clinical decision-making.
• Synthesis of information on LDL-C targets, non-fasting lipid use, and risk-enhancing factor assessment.

Main Results:

• Updated LDL-C treatment targets for primary and secondary ASCVD prevention.
• Inclusion of non-fasting lipid profiles and new LDL cholesterol calculation methods.
• Recommendations for assessing risk-enhancing factors to guide statin and non-statin therapy decisions.
• Emphasis on individualized risk assessment for ASCVD.

Conclusions:

• The new guidelines necessitate greater involvement of laboratory medicine in ASCVD risk stratification and patient management.
• Clinical laboratorians can actively contribute to identifying at-risk individuals and collaborating with physicians.
• The evolving strategies for monitoring and lowering LDL-C present new avenues for laboratory professionals to enhance patient care.